Arcellx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACLX Nasdaq 8731 https://www.arcellx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcellx Inc

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely - Jun 23rd, 2022 2:50 pm
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel - Jun 21st, 2022 8:05 pm
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares - Jun 21st, 2022 8:01 pm
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering - Jun 16th, 2022 2:47 am
ASCO 2022: Surprising News in Cancer Research - Jun 10th, 2022 9:00 pm
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer - Jun 6th, 2022 8:09 pm
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting - Jun 3rd, 2022 8:00 pm
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting - May 27th, 2022 1:57 pm
Arcellx Appoints Michelle Gilson as Chief Financial Officer - May 23rd, 2022 8:05 pm
Arcellx Appoints Olivia Ware to Board of Directors - May 16th, 2022 8:01 pm
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results - May 12th, 2022 8:01 pm
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma - May 10th, 2022 8:01 pm
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma - May 9th, 2022 8:01 pm
Here's What Arcellx, Inc.'s (NASDAQ:ACLX) Shareholder Ownership Structure Looks Like - May 9th, 2022 2:00 pm
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference - May 5th, 2022 8:01 pm
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 27th, 2022 2:00 pm
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting - Apr 8th, 2022 5:00 pm
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results - Mar 24th, 2022 8:01 pm
Arcellx Announces Participation at the Barclays Global Healthcare Conference - Mar 10th, 2022 9:26 pm
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 - Mar 8th, 2022 10:25 pm